Targeting VEGF receptors 1–3, AXL, MET, RET, KIT, FLT3, ROS1, MER, TYRO3, TRKB and TIE-2, the mechanism of cabozantinib inhibits both the VEGF pathways, and downstream targets MET and AXL which are implicated in tumour resistance in patients treated with VEGF therapy alone, such as sunitinib (14, 15). This evidence concerns the gene MET and neoplasm.